Pharma companies have reported weak Q3FY22 earnings with Solara Active reporting revenue decline of 76 percent on a year on year basis. Aurobindo Pharma's US sales disappointed and Q3 margins too declined to 16.9 percent versus 21.5 percent in Q3FY21.
Watch video for a report card on pharma sectors Q3 earnings.